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The aberrant expression of squamous lineage
markers in pancreatic ductal adenocarcinoma (PDA)
has been correlated with poor clinical outcomes.
However, the functional role of this putative transdif-
ferentiation event in PDA pathogenesis remains
unclear. Here, we show that expression of the tran-
scription factor TP63 (DNp63) is sufficient to install
and sustain the enhancer landscape and transcrip-
tional signature of the squamous lineage in human
PDA cells. We also demonstrate that TP63-driven
enhancer reprogrammingpromotesaggressive tumor
phenotypes, including enhanced cell motility and
invasion, and an accelerated growth of primary PDA
tumors and metastases in vivo. This process ulti-
mately leads to a powerful addiction of squamous
PDA cells to continuous TP63 expression. Our study
demonstrates the functional significance of squa-
mous transdifferentiation in PDA and reveals TP63-
based reprogramming as an experimental tool for
investigating mechanisms and vulnerabilities linked
to this aberrant cell fate transition.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is an aggressive
malignancy that typically presents at an advanced stage and is
refractory to most available treatments, with a median 5-year
survival rate of <8% (Siegel et al., 2018). This malignancy is typi-
cally initiated by an activating mutation in KRAS in a ductal or an
acinar cell of the pancreas, which collaborates with the loss of
tumor suppressor genes to drive PDA progression (Aguirre
et al., 2003; Hingorani et al., 2003, 2005). Despite our deep
understanding of the genetic drivers and the molecular patho-
genesis of PDA, pathway-specific targeted therapies have yet
to be implemented in the management of disease. Among the
numerous challenges in advancing targeted therapies in PDACell Repo
This is an open access article under the CC BY-Nis the profound heterogeneity of tumor cell phenotypes within
the current histology-based definition of this disease, which
limits our ability to predict responses to targeted agents.
Dynamic transitions in cell fate are one important source of in-
ter- and intra-tumoral heterogeneity in PDA. For example, exper-
iments in mouse models have shown that PDA can originate in a
pancreatic acinar cell, which transdifferentiates into a ductal cell
following the introduction of mutant Kras (Ferreira et al., 2017;
Guerra et al., 2007). In later stages of disease progression, it is
known that PDA can transiently lose the expression of epithelial
cell markers and gain mesenchymal features, in association with
metastatic spread (Genovese et al., 2017; Krebs et al., 2017;
McDonald et al., 2017; Rhim et al., 2012). Moreover, a subset
of PDA tumors exhibit epigenetic silencing of endodermal cell
fate determinants, including hepatocyte nuclear factor 1 homeo-
box A (HNF1A), HNF1B, HNF4A, and Kruppel-like factor 5
(KLF5), in association with a stable epithelial-to-mesenchymal
fate transition (David et al., 2016; Diaferia et al., 2016). We
have recently shown that mouse and human PDA tumors can
upregulate the pioneer factor Forkhead box A1 (FOXA1), which
leads to the activation of an embryonic foregut endoderm
enhancer landscape to endow tumor cells with metastatic po-
tential (Roe et al., 2017). Collectively, these studies highlight
aberrant cell fate transitions as a hallmark property of PDA,
which can be understood mechanistically by epigenomic map-
ping of the global enhancer configuration.
It has long been recognized that a subset of PDA tumors ac-
quire features of the squamous epithelial lineage (Morohoshi
et al., 1983), although the clinical relevance of this aberrant cell
fate transition is not well understood. Squamous epithelial cells
are a specialized cell type found in the epidermis, oropharynx,
and other anatomical locations, but this cell type does not exist
in the normal pancreas (Basturk et al., 2005). Nonetheless, histo-
logical analyses have revealed that a subset of human PDAs
possess an adenosquamous cell morphology, which is invari-
ably associated with the expression of TP63, a master regulator
of the normal squamous lineage (Mills et al., 1999; Soares and
Zhou, 2018). Recent transcriptome profiling of human tumor
specimens revealed that squamous lineage markers are ex-
pressed in as much as 25% of PDA tumors, which includes therts 25, 1741–1755, November 13, 2018 ª 2018 The Authors. 1741
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Figure 1. DNp63 Is Necessary and Sufficient to Drive Progenitor-to-Squamous Transcriptional Reprogramming in Human PDA Cells
(A and B) Transcription factor expression in squamous and progenitor subtypes of PDA. Scatterplots show expressed transcription factors ranked by their mean
log2 fold change in squamous versus progenitor patient samples from (A) Bailey et al. (2016) and (B) The Cancer Genome Atlas Research Network (2017).
(C) TP63 expression in human organoids derived from normal pancreatic tissue or PDA tumor samples at the indicated disease stage. Data are from the study by
Tiriac et al. (2018). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t test. See also Table S1.
(D) Survival curve of patients from the indicated study stratified according to high or low TP63 expression and for which survival data were available (Moffitt et al.,
2015). Samples were designated as TP63high or TP63low based on Z score expression values >0.35 or <0, respectively. p value was calculated using the log rank
(Mantel-Cox) test.
(E) Squamous-PDA and progenitor-PDA identity signatures defined from patient samples. The top 500 protein coding genes in squamous (n = 25) or progenitor
(n = 30) patient samples from the study by Bailey et al. (2016) were used to define the respective signatures. Heatmap shows expression levels of signature genes.
Scale bar indicates the standardized expression value. See also Table S2.
(F) TP63 expression in human PDA cell lines. Heatmap (top) shows RNA-seq analysis of human PDA cell lines ranked according to fold change in the median
expression level of genes corresponding to the squamous-PDA versus progenitor-PDA identity signatures; scale bar indicates log2 fold change. Bar chart
(middle) and western blot analysis (bottom) show TP63 expression in the indicated human PDA cell lines.
(legend continued on next page)
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adenosquamous tumors as well as specimens that lack clear
evidence of this cell morphology (Bailey et al., 2016). These
squamous-like PDAs are associated with an inferior prognosis
when compared to tumors lacking this transcriptional signature.
While the origin of a squamous identity in this disease is poorly
understood, it has been recognized that squamous-like PDAs
are enriched for loss-of-function mutations in the tumor-sup-
pressor genes TP53, KDM6A, KMT2C, and KMT2D (Andricovich
et al., 2018; Bailey et al., 2016).
A recent study used genetically engineered mice to show that
inactivation of the histone demethylase geneKdm6a, in conjunc-
tion with a KrasG12D mutation, led to the emergence of aggres-
sive PDAs that express squamous lineage markers (Andricovich
et al., 2018). In addition, it was shown that Kdm6a loss led to the
aberrant activation of enhancers at the Trp63 (the mouse ortho-
log of TP63), Runx3, and Myc loci. While this important study
validates Kdm6a as a genetic driver of PDA progression and
establishes a model system for interrogating this disease sub-
type, it did not address whether squamous transdifferentiation
was a cause or a consequence of the aggressive tumor pheno-
type. This is particularly relevant because KDM6A is a general
chromatin regulator, whichmay perform tumor-suppressor func-
tions irrespective of cell lineage (Ezponda et al., 2017).
In this study, we show that the DN isoform of the transcription
factor TP63 (DNp63) is a master regulator that specifies squa-
mous cell identity in PDA through dynamic regulation of the
enhancer landscape. Based on this observation, we use DNp63
to introduce squamous lineage characteristics into otherwise
isogenic PDAcell lines, whichwe use to interrogate the functional
consequences of this cell fate transition in vitro and in vivo. These
experiments implicate DNp63-driven enhancer reprogramming
as a mechanism that promotes PDA progression by endowing
tumors with enhanced growth and invasive potential. In addition,
we identify a network of oncogenic target genes sustained by
DNp63 that operate in the squamous subtype of PDA. In addition
to validating the functional significance of squamous transdiffer-
entiation in PDA, our study suggests that targeting the DNp63
transcriptional network may have therapeutic potential in this
aggressive disease subtype.
RESULTS
TP63 Is Expressed in a Subset of Pancreatic Tumors that
Display a Squamous-like Transcriptional Signature and
Inferior Overall Survival
Prior studies have noted the expression of squamous lineage
markers in a poor-prognosis subtype of PDA (Bailey et al.,
2016). To investigate the functional importance of this cell fate(G and H) TP63 knock out in BxPC3 cells. (G) GSEA plots evaluating the sq
(H) Representative western blot analysis for the indicated proteins. RNA was extra
post-infection with sgRNAs, 3 days post-selection with G418.
(I and J) DNp63 expression in SUIT2 cells. (I) GSEA plots evaluating the squa
(J) Representative western blot analysis in SUIT2 cells for the indicated protiens
analyses on day 7 post-infection, 5 days following G418 selection.
(K and L) Acute DNp63 expression in progenitor-like PDA cells. (K) Representat
(L) Table summarizing RNA-seq data evaluating the squamous-PDA identity sign
extracted and whole-cell lysates were prepared for the respective analyses 48 h
See also Figure S1.transition, we first sought to identify the master regulator tran-
scription factor (TF), whose presence is sufficient to confer squa-
mous cell identity in PDA. To this end, we evaluated existing
transcriptome analyses of PDA tumors in search of TFs that
are selectively expressed in the squamous-like subtype of this
disease (Bailey et al., 2016; The Cancer Genome Atlas Research
Network, 2017). Among all of the TFs expressed in PDA, we
recovered TP63 expression as the most highly enriched in squa-
mous-subtype tumors, which is in accordance with prior obser-
vations and the known role of this TF in normal and neoplastic
squamous lineage contexts (Figures 1A, 1B, S1A, and S1B) (An-
dricovich et al., 2018; Bailey et al., 2016). In addition, we found
that endodermal TFs GATA6, HNF1A, HNF1B, and HNF4A are
often silenced in TP63-expressing tumors, which is consistent
with the mutually exclusive classification of PDA into progenitor
and squamous subtypes (Bailey et al., 2016). Notably, TP63 is
expressed at low levels in normal human and mouse pancreatic
epithelial cells, but it is aberrantly upregulated in 15%–26% of
primary human PDA tumors and metastatic lesions (Figures
S1C–S1F) (Boj et al., 2015; GTEx Consortium, 2015). To further
corroborate this finding, we turned to our recently established
collection of 56 human organoid cultures derived from normal
pancreatic tissue or PDA tumors (Tiriac et al., 2018). Using
RNA sequencing (RNA-seq) analysis, we verified that 20% of
PDA organoids express TP63, which increases in a stage-
dependent manner (Figure 1C; Table S1). Using RT-PCR anal-
ysis, we determined that the DN isoform of TP63 (DNp63) is
specifically expressed in these samples, which is known to be
the oncogenic form of this TF (Figure S1G) (Rocco et al., 2006).
TP63 expression in PDA tumors was associated with an inferior
overall survival across each study analyzed (Figures 1D, S1H,
and S1I). Considering the known link between DNp63 and squa-
mous cell carcinoma (Keyes et al., 2011), we investigated
whether manipulating this TF would allow us to understand the
importance of squamous lineage characteristics in PDA.
Ectopic Expression of DNp63 Is Sufficient to Drive
Squamous Transcriptional Reprogramming in PDA Cell
Lines
To evaluate lineage reprogramming in PDA, we used transcrip-
tome analysis of PDA tumors from Bailey et al. (2016) to define
gene expression signatures that discriminate squamous from
progenitor cell identity in this disease (Figure 1E; Tables S2
and S3). The squamous-PDA identity signature includes known
markers of the squamous cell lineage, including TP63, KRT5,
KRT6A, S100A2, and PTHLH (Kaufmann et al., 2001; Shrestha
et al., 1998; Kitazawa et al., 1991). We interrogated these signa-
tures in RNA-seq data obtained from eight human PDA cell lines,uamous-PDA and progenitor-PDA identity signatures upon TP63 knockout.
cted and whole-cell lysates were prepared for the respective analyses on day 5
mous-PDA and progenitor-PDA identity signatures upon DNp63 expression.
. RNA was extracted and whole-cell lysates were prepared for the respective
ive western blot analysis in the indicated cell lines for the indicated proteins.
ature upon induction of DNp63 expression in the indicated cell lines. RNA was
r following dox administration.
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Figure 2. A Unique Enhancer Landscape Linked to DNp63 Occupancy in PDA
(A) Heatmap representation of unsupervised hierarchical clustering of nine human cell lines or organoids representing PDA or normal pancreatic ducts based on
H3K27ac occupancy at total H3K27ac ChIP-seq peaks. Scale bar indicates Pearson correlation coefficient. Normal organoids: hN34, hN35; PDA organoids: hF3,
hT85; PATU: PATU8988S.
(B) ChIP-seq density plots of TP63 and H3K27ac enrichments at squamous elements (top) or a set of 1,336 control H3K27ac regions (bottom) in the indicated cell
lines. Each row represents a 10-kb interval centered on the midpoint of each H3K27ac peak.
(C) ChIP-seq profiles of TP63 (top track) and H3K27ac at representative squamous elements close toKRT5 and KRT6A (left), TRIM29 (middle), and PTHLH (right).
(legend continued on next page)
1744 Cell Reports 25, 1741–1755, November 13, 2018
which allowed us to rank each line based on its degree of resem-
blance to progenitor or squamous cell fates (Figure 1F). In accor-
dance with the observations above in human tumors, TP63
mRNA and protein were only detected in the most squamous-
like PDA cell linesMIAPaca2 and BxPC3 (Figure 1F). We focused
our subsequent analysis of endogenous TP63 in BxPC3 cells as
they express the relevant DN isoforms, which is in contrast to
MIAPaca2 cells, which instead express the tumor-suppressive
transactivation domain (TA) isoform of TP63 (TAp63) (Figure S1J)
(Yang et al., 1998). Using CRISPR-Cas9, we targeted TP63 in
BxPC3 cells with two independent single guide RNAs (sgRNAs)
and performed RNA-seq analysis. Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) revealed that the loss of TP63
led to diminished expression of the squamous-PDA identity
signature, which was further supported by an independent
Gene Ontology analysis (Figures 1G and S1K). These gene
expression changes were not limited to mRNA levels, as loss
of KRT5/6 and S100A2 protein was also verified by western
blotting (Figure 1H). In addition, inactivating TP63 also led to a
paradoxical induction of the progenitor-PDA identity signature,
suggesting an antagonistic relation between these two cell fates
in PDA. These experiments suggest that the squamous tran-
scriptional signature in PDA is enforced by the presence of TP63.
Having validated the causal relation between TP63 and the hu-
man PDA tumor-derived squamous transcriptional signature, we
next evaluated whether ectopic expression of TP63 would be
sufficient to endow PDA cell lines with the transcriptional profile
of the squamous cell lineage. To this end, we initially lentivirally
transduced the DNp63 cDNA into two progenitor-like PDA cell
lines, SUIT2 and PATU8988S (Figure 1F; Table S4). RNA-seq
analysis of these cells revealed that DNp63 enhanced the
expression of squamous-PDA identity gene signatures in both
settings (Figures 1I, S1L, and S1M), which we also verified by
western blotting for squamous markers KRT5/6 and S100A2
(Figure 1J). Consistent with the findings above, DNp63 dimin-
ished the progenitor-PDA identity signature in both settings (Fig-
ures 1I and S1M). To investigate the sufficiency of DNp63 to
install squamous transcriptional features across a broader panel
of PDA cells in a more acute manner, we generated cell lines in
which DNp63 expression was under the control of doxycycline
(dox). The addition of dox led to robust activation of DNp63
expression (Figures 1K and S1N), and this was accompanied
by potent activation of the squamous-PDA identity gene signa-
ture in all of the human cell lines tested, as well as PDA cells
derived from KPC (Kras+/LSL-G12D; Trp53+/LSL-R172H;
Pdx1-Cre) mice (Figure 1L). These results demonstrate the ne-
cessity and sufficiency of DNp63 to produce squamous-like fea-
tures in PDA.(D) GSEA plots evaluating the relative expression of genes proximal to squamous
et al. (2016). See also Table S5.
(E) Pie chart showing the genomic distribution of squamous elements according t
TSS, transcription start site.
(F) Ontology analysis of genes located nearest to squamous elements versus co
process (left) and disease ontology (right) are shown.
(G) Representation of motifs enriched at squamous elements versus control elem
fold change in p value. The TP53 position weight matrix is represented as TP53
control elements as determined by p value.
See also Figure S2.A Unique Enhancer Configuration Linked to DNp63
Genomic Occupancy in PDA
Prior work has shown that lineage transitions in PDA are medi-
ated through alterations of the chromatin state and the associ-
ated landscape of active enhancer elements (Diaferia et al.,
2016; McDonald et al., 2017; Roe et al., 2017). However, it has
yet to be determined whether a distinct enhancer-chromatin
configuration exists in squamous versus progenitor subtypes
of PDA. To address this, we performed chromatin immunopre-
cipitation sequencing (ChIP-seq) analysis in 10 human cell lines
or organoids representing PDA or normal pancreatic ducts to
map the genome-wide pattern of histone H3 lysine 27 acetylation
(H3K27ac), which is a covalent modification that demarcates
active cis-regulatory elements (Rada-Iglesias et al., 2011). These
cultures include PDAs that express TP63 and other squamous
lineage markers, including the TAp63-expressing MIAPaca2
cells and two DNp63-expressing PDAs (BxPC3 cells and the
hF3 organoid), whereas the other cultures express the progeni-
tor-PDA identity signature (Figures 1F and S2A). An unsuper-
vised clustering analysis of the global pattern of H3K27ac
enrichment across the 10 cultures revealed three major groups
(Figures 2A and S2B). The most progenitor-like samples formed
two distinct clusters: one containing PATU8988S, hT85, and the
two normal ductal organoids, and the other containing AsPC1,
HPAFII, and SUIT2 cells. We found that the two DNp63-express-
ing squamous-like cultures (BxPC3 and hF3) formed a distinct
cluster, suggesting a unique enhancer-chromatin configuration
linked to this cell fate (Figure 2A). Of note, the TAp63-expressing
MIAPaca2 cell line did not cluster together with the two DNp63-
expressing cultures, indicating that this cell line is epigenetically
distinct (Figure S2B).
We next extracted the subset of H3K27ac-enriched regions
that correlated with the BxPC3 and hF3 cell cluster, which iden-
tified 1,336 regions that we termed ‘‘squamous elements’’ (Fig-
ures 2B and 2C; Table S5). Squamous elements were almost
entirely found at distal (non-promoter) sites and were located
near genes that were preferentially expressed in the squamous
subtype of PDA, suggesting that they represent enhancer ele-
ments (Figures 2D and 2E). In addition, an unbiased ontology
analysis of genes located near these elements confirmed their
association with the normal and neoplastic squamous lineage
(e.g., epidermis development, squamous cell carcinoma) (Fig-
ure 2F). KRT5/6, TRIM29, and PTHLH are examples of squa-
mous lineage genes located in proximity to squamous elements
(Figure 2C). These data complement prior transcriptional obser-
vations (Bailey et al., 2016) by suggesting that a subset of PDA
tumors display an enhancer landscape resembling the squa-
mous cell lineage.elements in squamous or progenitor patient samples from the study by Bailey
o annotation of H3K27ac peaks by HOMER. TTS, transcription termination site;
ntrol elements using GREAT. Gene Ontology (GO) terms related to biological
ents using TRAP. Human promoters were used as the comparison library. Left:
family motif. Right: enrichment of the TP53 motif at squamous elements and
Cell Reports 25, 1741–1755, November 13, 2018 1745
Figure 3. DNp63 Expression Is Sufficient to Install and Maintain a Squamous Enhancer Landscape in PDA
(A and B) TP63 knockout in BxPC3 cells and H3K27ac ChIP-seq analysis. (A) Metagene representation of H3K27ac signal in squamous elements (left), random
control elements (middle), and all of the H3K27ac elements (right) in TP63 knockout and control cells. (B) ChIP-seq profiles of TP63 (top track) and H3K27ac at
representative squamous elements close to KRT5 and KRT6A (top) and PTHLH (bottom). BxPC3-Cas9 cells were cross-linked and prepared for ChIP-seq
analysis on day 5 post-infection, 3 days following G418 selection, with two independent TP63 or control sgRNAs (sgNEGs).
(C and D)DNp63 expression in SUIT2 cells and H3K27ac ChIP-seq analysis. (C) Metagene representation of H3K27ac signal in squamous elements (left), random
control elements (middle), and all of the H3K27ac elements (right) in SUIT2 cells expressingDNp63 or control cells. (D) ChIP-seq profiles of ectopically expressed
(legend continued on next page)
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We next investigated the causal role of TP63 in activating
squamous elements in the context of PDA. Using a TF affinity
prediction (TRAP) motif enrichment analysis (Thomas-Chollier
et al., 2011), we identified a motif recognized by TP63 as the
most enriched sequence within the entire group of squamous el-
ements (Figure 2G) (Yang et al., 1998). This finding led us to
perform ChIP-seq analysis of endogenous TP63 in BxPC3 cells,
which revealed pervasive TP63 occupancy at squamous ele-
ments. In contrast, we observed much lower levels of TP63
occupancy at a control set of H3K27ac-enriched locations
(Figures 2B, 2C, S2C, and S2D). These findings indicate that
squamous elements are linked to the occupancy of TP63 in the
squamous-like subtype of PDA.
Having established a link between TP63 and squamous ele-
ments in PDA, we next evaluated the functional requirement of
TP63 to activate these cis-regulatory elements. We used ChIP-
seq to profile H3K27ac in BxPC3-Cas9 cells following acute
transduction with TP63 sgRNAs (Figure S3A). This analysis
revealed a selective reduction in H3K27ac at squamous ele-
ments, whereas the levels of this histone mark were unchanged
at control locations (Figures 3A and 3B). To complement this
loss-of-function experiment, we next evaluated whether expres-
sion of TP63 would be sufficient to activate squamous elements.
To this end, we performed ChIP-seq analysis in control or
DNp63-expressing SUIT2 cells to profile the impact on the
enhancer landscape. While parental SUIT2 cells possess back-
ground levels of H3K27ac enrichment at squamous elements,
introducing DNp63 led to a selective induction of H3K27ac at
these locations, which now resembled the enhancer configura-
tion observed in hF3 and BxPC-3 cells that possess endogenous
DNp63 expression (Figures 3C, 3D, and S3B). To further investi-
gate the sufficiency of DNp63 to install squamous enhancers
across a broader panel of PDA cells, we performed ChIP-seq
analysis of H3K27ac enrichment following dox-inducible expres-
sion of DNp63 in the four most progenitor-like human PDA cell
lines. In each cell line tested, acute induction ofDNp63 produced
potent and selective acetylation of squamous elements (Figures
3E and S3C). Together with the transcriptional profiling results
above, these findings indicate that toggling the function of
DNp63 allows for the experimental manipulation of the enhancer
landscape that underlies the squamous subtype of PDA.
Phenotypic Consequences of DNp63-Mediated
Enhancer Reprogramming
We reasoned that the phenotypic characterization of SUIT2 cell
lines transduced with DNp63 provided an ideal system for prob-
ing the functional significance of this enhancer reprogramming
event in this disease. Under tissue culture monolayer conditions,
we found that expression of DNp63 led to a reduced rate of
SUIT2 cell proliferation, but enhanced cell motility in a scratch-
wound assay (Figures 4A and 4B). In three-dimensional growth
assay conditions in media supplemented with Matrigel (CorningFLAG-tagged TP63 (top track) and H3K27ac at representative squamous element
linked and prepared for ChIP-seq analysis on day 7 post-infection, 5 days post-
(E) Metagene representation of H3K27ac signal in squamous elements (top) and
following dox-inducible expression of DNp63 or GFP as a control. Cells were cros
See also Figure S3.Life Sciences), DNp63-expressing SUIT2 cells formed fewer col-
onies than control cells; however, the colonies that formed were
significantly larger and possessed more invasive projections
(Figures 4C and S4A). These findings suggested that DNp63
expression alters the growth and invasive characteristics of
PDA cells in vitro.
To extend these findings into themore relevant in vivo environ-
ment, we transplanted the DNp63-reprogrammed or control
SUIT2 cells harboring a luciferase transgene into the pancreas
of immunodeficient mice and monitored tumor progression us-
ing bioluminescent imaging. Following transplantation of equal
numbers of cells, we found at initial time points that DNp63-
expressing SUIT2 cells displayed less efficient engraftment
levels in comparison to their control counterparts, which is in
accordance with experiments performed in vitro (Figures 4D
and S4B). However, the DNp63-expressing cells proceeded to
expand more rapidly compared to controls and gave rise to
significantly larger tumors at the endpoint of the experiment
(Figures 4D and 4E). When injected into the tail vein of mice,
DNp63-expressing cells colonized the lung parenchyma with
similar kinetics to control mice, but formed larger metastatic
lesions at the terminal endpoint of the experiment (Figures 4F
and S4C). Histological examination of the primary tumors
revealed that DNp63 expression gave rise to poorly differenti-
ated tumors, and immunohistochemical staining confirmed the
upregulation of squamous lineage markers (Figure 4G). These
data suggest that enhancer reprogramming imposed by
DNp63 confers enhanced growth characteristics to PDA cells
in vivo in both primary and metastatic tissue contexts.
Squamous PDA Cells Become Addicted to DNp63
The findings above led us to investigate whether squamous PDA
cells become addicted to DNp63 to sustain their growth poten-
tial. Using CRISPR-Cas9 competition-based proliferation assays
evaluating the effects of individual sgRNAs, we validated that
TP63 is essential for the growth of BxPC3 cells, but dispensable
in other PDA contexts (Figures 5A, S5A, and S5B). To rule out any
CRISPR-induced artifacts, we also targeted TP63 in BxPC3 cells
using small hairpin RNAs (shRNAs) and observed a similar loss of
proliferative potential and highly concordant gene expression
changes to those seen following TP63 inactivation with sgRNAs
(Figures S5C–S5F). Moreover, knock down of TP63 in the hF3
PDA organoid sample also resulted in a growth arrest and sup-
pression of the squamous-PDA identity signature (Figures 5B,
5C, and S5G). The growth arrest phenotype in BxPC3 cells could
be rescued by expressing a CRISPR-resistant cDNA encoding
DNp63, with the degree of rescue correlating with the levels of
reconstituted DNp63 protein (Figures 5D, 5E, and S5H). We
next evaluated the impact of DNp63 inactivation on PDA growth
in vivo by transducing BxPC3-Cas9-luciferase cells with TP63
sgRNAs before transplantation into the pancreas or the tail
vein of immunodeficient mice. By monitoring tumor progressions close to KRT5 and KRT6A (top) and PTHLH (bottom). SUIT2 cells were cross-
G418 selection.
random control elements (bottom) in the indicated progenitor-like PDA cells
s-linked and prepared for ChIP-seq analysis 48 hr following dox administration.
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Figure 4. Phenotypic Consequences of DNp63-mediated Enhancer Reprogramming
(A–C) In vitro consequences ofDNp63-mediated squamous lineage reprogramming. SUIT2 cells were infectedwithDNp63 cDNAor an empty vector and assayed
on day 7 post-transduction, day 5 post-G418 selection. (A) Line graph showing in vitro cell growth as determined by CellTiter-Glo (Promega) assay. Means
±SEMs are shown. n = 3. (B) Bar chart (left) showing quantification of scratch assays at the indicated time points post-seeding, and representative images are
shown (right). Means + SEMs are shown. n = 3. (C) Bar chart (left) showing quantification of colony size in three-dimensional (3D) Matrigel colony formation assays
on day 7 post-plating, day 14 post-viral transduction. Colony size was measured using ImageJ software (NIH). Means + SEMs are shown. n = 3. Representative
images at day 7 are shown (right).
(D–G) In vivo consequences of DNp63-mediated squamous lineage reprogramming. SUIT2 cells harboring a luciferase transgene were infected with DNp63
cDNA or an empty vector and transplanted on day 5 post-viral transduction, day 3 post-G418 selection. (D) Line graph (left) shows quantification of the biolu-
minescence signal following orthotopic injection of 50,000 cells to the pancreas of NSGmice. Means ± SEMs are shown. Mice were imaged on days 7, 11, 14, 17,
and 20 post-transplantation, and representative images are shown (right). n = 4mice per group. (E) Bright-field images of tumors removed frommice shown in (D)
on day 21 post-transplantation. (F) Line graph (left) shows quantification of bioluminescence signal following injection of 100,000 cells via the tail vein of NSG
mice. Means ± SEMs are shown. Mice were imaged every 2 days from days 7 to 23 post-transplantation, and representative images are shown (right panel).
n = 5 mice per group. Scale bar indicates luminescence signal. (G) Representative H&E (left) or immunohistochemical staining for the indicated proteins of tumor
samples from (E). Scale bar indicates 50 mm. *p < 0.001 by two-way ANOVA with Sidak’s test for multiple comparisons.
See also Figure S4.using bioluminescent imaging, we found that TP63 inactivation
resulted in complete arrest of tumor growth when compared to
control cells, both at the primary site and in the lung parenchyma
(Figures 5F–5I and S5I). These results are complementary to our
experiments in reprogrammed SUIT2 cells and suggest that
squamous-like PDA tumors become addicted to DNp63 to sus-
tain tumor growth in vivo.1748 Cell Reports 25, 1741–1755, November 13, 2018We next investigated which target genes within the DNp63-
reprogrammed enhancer landscape may be relevant to the
progression of PDA. For this purpose, we analyzed our collec-
tive RNA-seq and ChIP-seq datasets in search of high-confi-
dence DNp63 target genes. By intersecting the genes downre-
gulated following TP63 ablation in BxPC3 cells with the genes
upregulated following DNp63 expression in SUIT2 cells, we
Figure 5. DNp63 Is a Dependency in Squa-
mous PDA Cells
(A) Competition-based proliferation assay in
BxPC3 cells following infection with the indicated
sgRNAs linked to GFP. Means + SEMs are shown.
n = 3.
(B and C) TP63 knockdown in hF3 organoids. (B)
Representative western blot analysis for the indi-
cated proteins in the indicated conditions. Whole-
cell lysates were prepared on day 8 post-infection
with shRNAs, 5 days post-selection with puro-
mycin. (C) Line graph showing in vitro cell growth
as determined by CellTiter-Glo assay following
infection with the indicated shRNAs. Means ±
SEMs are shown. n = 3. *p <0.01 by two-way
ANOVA with Sidak’s test for multiple compari-
sons.
(D and E) TP63 sgRNA/cDNA rescue assay in
BxPC3 cells. (D) Competition-based proliferation
assay in BxPC3 cells stably expressing the indi-
cated cDNA following infection with the indicated
sgRNAs linked to GFP. Means + SEMs are
shown. n = 3. (E) Representative western blot
analysis for the indicated proteins in the indicated
conditions. Whole-cell lysates were prepared on
day 5 post-infection with sgRNAs; the GFP per-
centage was >95% in each condition for western
blot analysis. DNp63 WT, wild-type DNp63;
DNp63 Mut#3, DNp63 cDNA resistant to
sgTP63#3; DNp63 Mut#4, DNp63 cDNA resistant
to sgTP63#4.
(F and G) In vivo consequences of TP63
knockout. BxPC3-Cas9 cells expressing a lucif-
erase transgene were infected with two inde-
pendent TP63 or control (sgNEG) sgRNAs before
transplantation on day 5 post-infection, 3 days
post-G418 selection. Line graphs show quantifi-
cation of bioluminescence signal following injec-
tion of 100,000 cells to the pancreas (F) or
250,000 cells via the tail vein (G) of NSG mice.
Means ± SEMs are shown.
(H and I) Representative bioluminescence images
at the indicated days post-transplant following
injection of cells to the pancreas (H) or via the tail
vein (I) of NSG mice. Scale bar indicates lumi-
nescence signal. n = 4–5 mice per group. *p <
0.01 by two-way ANOVA with Sidak’s test for
multiple comparisons.
See also Figure S5.recovered 63 candidate DNp63 targets. We reduced this list to
58 genes by requiring that a target gene be located near a peak
of TP63 occupancy detected by ChIP-seq (Figure 6A; Table S6).
As expected, these 58 genes were preferentially expressed in
the squamous subtype of PDA and included the previously
described squamous lineage genes KRT5, PTHLH, and
S100A2 (Figure S6A). From a literature search, we note that
many of the DNp63 target genes encode proteins that have
been causally implicated in promoting tumor cell growth and
cancer progression in prior studies, such as HRAS and
CXCL8 (Grabocka et al., 2014; Young et al., 2013) (Figures
6B–6D; Table 1). Consistent with these observations, thesegenes are concordantly downregulated following TP63 knock-
down in the hF3 PDA organoid (Figures S6B and S6C). We addi-
tionally found that MYC mRNA and protein were significantly
downregulated following TP63 inactivation, which is in accord
with the elevated level of the MYC transcriptional network in
squamous-subtype PDA tumors (Bailey et al., 2016) (Figures
S5E, S6D, and S6E). Our ChIP-seq analysis identified several
TP63-occupied squamous elements at the MYC locus, which
may account for TP63-mediated MYC regulation (Figure S6F).
This analysis reveals a network of cancer-promoting DNp63
targets that are activated during enhancer reprogramming in
squamous-subtype PDA.Cell Reports 25, 1741–1755, November 13, 2018 1749
Figure 6. The Core Circuitry of DNp63-
Mediated Enhancer Reprogramming in
Squamous PDA Cells
(A) Venn diagram showing the overlap of signifi-
cantly downregulated genes in BxPC3-Cas9 cells
and upregulated genes in SUIT2 cells following
infection with sgRNAs targeting TP63 or expres-
sion ofDNp63 cDNA, respectively (fold change >2,
p < 0.01). See also Table S6.
(B) Bar graph showing the mean log2 fold change
of example genes from (A). See also Table 1.
(C and D) ChIP-seq profiles of TP63, FLAG-tagged
DNp63, and H3K27ac at the DNp63 target genes
HRAS (C) and CXCL8 (D) following TP63 knockout
in BxPC3-Cas9 cells or expression of DNp63 in
SUIT2 cells.
See also Figure S6.DISCUSSION
Prior studies have shown that squamous lineage markers
become aberrantly expressed in a subset of aggressive PDAs
(Andricovich et al., 2018; Bailey et al., 2016; Morohoshi et al.,
1983). Here, we have pursued the causal role of squamous trans-
differentiation in PDA progression using an experimental
approach that exploits the master regulator concept, which is
classically defined by the ability of certain TFs to drive cell fate
transitions by functioning at the apex of a gene regulatory
network (Davis et al., 1987). The gain- and loss-of-function epi-
genomic analysis presented in this study validates DNp63 as a
master regulator of the squamous identity in PDA, which is
consistent with the known role of this TF in normal squamous
epithelial tissues and in squamous cell carcinomas (Soares
and Zhou, 2018). We have used the master regulator property
of DNp63 to endow PDA cells with the enhancer landscape
and transcriptional signature associated with squamous identity
without the confounding effect of altering the tumor genotype.
This approach leverages recent transcriptome analyses of
human PDA to validate that DNp63-mediated reprogramming
produced in cell lines faithfully recapitulates the transcriptional
profile seen in human tumors (Bailey et al., 2016; The Cancer
Genome Atlas Research Network, 2017). This approach allowed
us to demonstrate that a DNp63-driven enhancer landscape
promotes PDA progression in vivo.
Our study highlights the utility of enhancer profiling as a strat-
egy for mapping cell fate transitions in cancer and for the vali-
dation of lineage reprogramming by master regulators in an
experimental setting. In specific cancers, enhancer profiling
has revealed novel tumor subtypes that reflect an alternative
cell of origin (Lin et al., 2016). In pancreatic cancer, enhancer
profiling has been used to provide insight into transdifferen-1750 Cell Reports 25, 1741–1755, November 13, 2018tiation mechanisms of cellular lineage.
For example, prior work in cancer cell
lines revealed an enhancer configura-
tion established by endodermal lineage
TFs (e.g., KLF5), which becomes extin-
guished in cell lines with mesenchymal
features (Diaferia et al., 2016). We previ-ously used a mouse organoid progression model of PDA to
reveal the activation of an embryonic foregut enhancer land-
scape by FOXA1, which promotes disease progression and
metastatic spread (Roe et al., 2017). However, neither of these
prior studies focused on the squamous subtype of PDA, which
has only recently been recognized as a common form of PDA
with an exceptionally poor prognosis (Bailey et al., 2016). A
major finding in our study is that massive alterations of the
enhancer landscape occur upon acquiring a squamous identity,
which strongly suggests that the previously described squa-
mous transcriptional signature in PDA reflects a bona fide cell
fate transition in this disease.
Our prior studies highlighted the role of TFs in driving the reor-
ganization of enhancers and promoting disease progression
and metastatic spread in PDA, identifying FOXA1 as a driver
of this process (Roe et al., 2017). However, in contrast to
FOXA1, which requires cooperating TFs to achieve effective
enhancer activation in PDA, here, we demonstrate that DNp63
expression alone is sufficient to install squamous enhancer ele-
ments and promote aggressive disease characteristics in this
disease. The powerful effects of DNp63 on the enhancer land-
scape of PDA cells are also reflected in their ensuing addiction
to the continued expression of this TF, as well as an exception-
ally poor prognosis in this group of PDA patients, which we did
not observe to be the case for FOXA1 (Roe et al., 2017). Thus,
although these studies highlight a common theme of enhancer
reprogramming in driving disease progression in PDA, they also
highlight that the functional and clinical outputs of this reprog-
ramming event can be distinct and are determined by the
master regulator TFs deregulated in this disease.
One unexpected result in our study is that DNp63 expression
augments PDA tumor cell growth under in vivo conditions
and in three-dimensional cultures, but not in two-dimensional
Table 1. DNp63 Target Genes with Oncogenic Potential
Putative DNp63 Target Gene Oncogenic Phenotype Reference
S100A2 migration and metastasis Bulk et al., 2009
CXCL1 tumor growth, tumor cell survival, angiogenesis,
myeloid cell recruitment
Acharyya et al., 2012
STC1 tumor growth, tumor cell survival, metastasis Pen˜a et al., 2013
PTHLH metastasis, tumor growth, tumor cell survival Iguchi et al., 1996; Urosevic et al., 2014
CCL20 metastasis, myeloid cell recruitment, EMT Ye et al., 2016
CXCL8 angiogenesis, tumor growth and migration, metastasis,
myeloid cell recruitment
Waugh and Wilson, 2008
NRG1 tumor growth Sheng et al., 2010
ARL4D tumor cell migration Li et al., 2007
IL6R tumor progression and inflammation Hodge et al., 2005
HAS3 tumor growth, angiogenesis, ECM deposition, migration Itano et al., 2002; Liu et al., 2001
AREG tumor growth, cell migration, chemoresistance Peterson et al., 2015; Zhang et al., 2009
LPXN tumor progression Kaulfuß et al., 2009
AK4 tumor invasion and metastasis Jan et al., 2012
ADORA2B invasion, migration and metastasis Desmet et al., 2013
HRAS tumor cell growth, survival, and maintenance Grabocka et al., 2014; Young et al., 2013
ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition.
See also Figure 6.monolayer conditions. This finding can be explained, as many of
the DNp63 target genes identified in this study have been previ-
ously shown to drive migratory and invasive properties of tumor
cells, such as HAS3 and S100A2 (Bulk et al., 2009; Itano et al.,
2002). Moreover, a number of DNp63 target genes encode pro-
teins that can modulate the tumor microenvironment. This in-
cludes the genes CXCL1, CXCL8, and CCL20, which encode
pro-inflammatory cytokines that can drive tumor progression
through non-cell-autonomous mechanisms, such as promoting
angiogenesis and the recruitment of tumor-propagating myeloid
cells (Acharyya et al., 2012; Waugh and Wilson, 2008; Ye et al.,
2016). It is also noteworthy that some DNp63 target genes may
have effects that reach beyond the local microenvironment.
For example, the gene PTHLH encodes a secreted hormone
that is implicated in hypercalcemia of malignancy and cachexia
(Burtis et al., 1987; Iguchi et al., 1996; Kir et al., 2014; Urosevic
et al., 2014). We hypothesize that DNp63-driven enhancer re-
programming and hijacking of the squamous lineage program
provide an efficient means for PDA cells to acquire capabilities
for sustained invasive growth into the tissue parenchyma of the
pancreas and at distal sites. It may also play a systemic role dur-
ing the course of disease progression.
Prior studies have implicated a role forDNp63 as an oncogene,
such as in squamous cell carcinoma (Rocco et al., 2006). Diverse
mechanisms have been proposed to explain the tumor-promot-
ing function ofDNp63,which include antagonismof p53,modula-
tion of microRNAs, bypass of senescence, and enhanced cancer
stem cell activity (Keyes et al., 2011;Memmi et al., 2015; Su et al.,
2010; Yang et al., 1998). To our knowledge, our study is the first to
demonstrate that DNp63 is sufficient to reprogram the enhancer
landscape of PDA cells and confer properties of the squamous
cell lineage, thus implicating squamous transdifferentiation in tu-
mor progression. Of note, in vitro experiments performed usingour dox-regulated system in SUIT2 cells, whereby DNp63 was
transiently introduced and subsequently removed, suggest that
the addiction to DNp63 does not occur immediately following its
expression, but instead requires a longer period of transdifferen-
tiation before the addiction ensues (data not shown). It is impor-
tant to consider that the aberrant acquisition of a squamous iden-
tity in PDA occurs in the context of a highly mutated cancer
genome, which includes oncogenic KRAS and inactivation of
several tumor-suppressor genes, aswell as within the complexity
of the tumor microenvironment. Thus, it is likely that the genes
activated through themechanismof TP63-mediatedenhancer re-
programming collaborate with the milieu of established genetic
mutationswithin thecontext of aPDAcell topromote thisdisease.
The observation that squamous-like PDAs are enriched for mu-
tations in specific tumor suppressors suggests that certain geno-
typesmay bemore permissive for the acquisition of a squamous-
like identity in PDA (Andricovich et al., 2018; Bailey et al., 2016).
A recent study described a KrasG12D/Kdm6a/ mouse model
of PDA that forms tumors that express TP63 (Andricovich et al.,
2018). Because KDM6A mutations are enriched in squamous-
like human PDAs, the Andricovich et al. (2018) study establishes
how specific genotypes can predispose tumor cells to acquire
squamous attributes. However, mutations in KDM6A (and other
related chromatin regulators) only account for less than half of
the squamous PDA tumors (Bailey et al., 2016). This suggests
the existence of additional mechanisms that activate TP63
expression in PDA. Prior work has implicated genotoxic stress,
hypoxia, Notch ligands, and Hedgehog signals as regulating
TP63 expression, suggesting a possibility that non-geneticmech-
anisms in the pancreas microenvironment may also contribute to
the squamous lineage transition in PDA (Li et al., 2008; Petitjean
et al., 2008; Tadeu and Horsley, 2013; Xi et al., 2017). Moreover,
it also possible that other TFs participate in the acquisition ofCell Reports 25, 1741–1755, November 13, 2018 1751
squamous cell characteristics in PDA. For example, SOX2 can
function as a lineage oncogene in squamous cell carcinomas
(Bass et al., 2009), and MYC amplifications have been correlated
with adenosquamous variants of pancreatic cancer (Witkiewicz
et al., 2015). While our findings suggest a functional link between
MYC and DNp63, we did not find evidence for a role for SOX2 in
squamous transdifferentiation in PDA (data not shown). Never-
theless, our findings and the work of Andricovich et al. (2018) pro-
vide complementary evidence in human and murine systems,
respectively, to implicate the acquisition of a squamous-like iden-
tity as a contributor to PDA progression.
A major challenge in implementing cancer therapy is in identi-
fying tumor biomarkers that predict exceptional responses. In
this study, we have shown that introducing DNp63 into a PDA
cell line is sufficient to reprogram the epigenome and cell identity
to one that resembles human squamous-like PDA tumors. This
approach provides a powerful isogenic cell system for investi-
gating unique vulnerabilities linked with the squamous subtype
of PDA. For example, domain-focused CRISPR screening could
be applied to control and DNp63-expressing SUIT2 cells to
discover actionable targets that are linked with this cell fate tran-
sition (Shi et al., 2015). More broadly, our study calls attention to
the use of master regulator TFs as predictive biomarkers for tar-
geted therapies, thus implicating isogenic-reprogrammed cell
lines as a powerful tool for revealing dependencies linked with
specific cellular states.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS175B Mice
B Cell Lines
d METHOD DETAILS
B Plasmid Construction
B Lentiviral Production and Infection
B In Vitro Phenotypic Assays
B CRISPR-Based Targeting
B shRNA targeting in BxPC3 cells and hF3 organoids
B In Vivo Transplantation Experiments
B Histology and Immunohistochemistry
B Cell Lysate Preparation for Western Blot Analysis
B RNA Extraction and RT-PCR
B RNA-seq Library Construction
B ChIP and ChIP-Seq Library Construction
B RNA-Seq Data Analysis
B ChIP-Seq Analysis
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITYSUPPLEMENTAL INFORMATION
Supplemental Information six figures and seven tables and can be found with
this article online at https://doi.org/10.1016/j.celrep.2018.10.051.2 Cell Reports 25, 1741–1755, November 13, 2018ACKNOWLEDGMENTS
We would like to thank Rachel Rubino and Jill Habel from Cold Spring Harbor
Laboratory (CSHL) Animal Resources for technical assistance with the mouse
transplantation assays and John E. Wilkinson from the University of Michigan
School of Medicine for the analysis of mouse histopathology. In addition, we
thank the following CSHL shared resource core facilities: Animal and Animal
Imaging, Bioinformatics, and DNA Sequencing and Histology. T.D.D.S. was
supported by a grant from the State of New York, contract no. C150158.
C.R.V. was supported by Pershing Square Sohn Cancer Research Alliance,
Boehringer Ingelheim, theCold Spring Harbor Laboratory andNorthwell Health
Affiliation, the National Cancer Institute (NCI) 5P01CA013106-Project 4, and a
Career Development Award from the Pancreatic Cancer Action Network-
American Association for Cancer Research (AACR) 16-20-25-VAKO. D.A.T.
is supported by the Lustgarten Foundation of Pancreatic Cancer Research
and the NIH (NIH 5P30CA45508-29, 5P50CA101955-07, P20CA192996-03,
1U10CA180944-04, 1R01CA188134-01, and 1R01CA190092-04).
AUTHOR CONTRIBUTIONS
T.D.D.S. and C.R.V. designed experiments, analyzed the data, and wrote the
manuscript. T.D.D.S. performed the majority of the experiments. Y.X., K.M.,
H.T., C.R.C., D.M.-S., and J.P.M. assisted with the experiments. C.R.V. and
D.A.T. supervised the research.
DECLARATION OF INTERESTS
C.R.V. is an advisor to KSQ Therapeutics and receives research funding from
Boehringer Ingelheim. D.A.T. is a member of the scientific advisory boards of
Surface Oncology, Leap Therapeutics, MabImmune, VividBiosciences, and
Bethyl Antibodies. D.A.T. has stock ownership in Surface Oncology and
Leap Therapeutics. D.A.T. receives research support fromONO and Fibrogen.
Received: June 27, 2018
Revised: September 6, 2018
Accepted: October 12, 2018
Published: November 13, 2018
REFERENCES
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P.G.,
Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V.E., et al. (2012). A
CXCL1 paracrine network links cancer chemoresistance and metastasis.
Cell 150, 165–178.
Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J.,
Redston, M.S., and DePinho, R.A. (2003). Activated Kras and Ink4a/Arf defi-
ciency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
Genes Dev. 17, 3112–3126.
Aiello, N.M., Rhim, A.D., and Stanger, B.Z. (2016). Orthotopic injection of
pancreatic cancer cells. Cold Spring Harb. Protoc. 2016, pdb.prot078360.
Andricovich, J., Perkail, S., Kai, Y., Casasanta, N., Peng, W., and Tzatsos, A.
(2018). Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific
Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Cancer Cell 33, 512–526.e8.
Bailey, T.L., Boden, M., Buske, F.A., Frith, M., Grant, C.E., Clementi, L., Ren,
J., Li, W.W., and Noble, W.S. (2009). MEME SUITE: tools for motif discovery
and searching. Nucleic Acids Res. 37, W202–W208.
Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C.,
Miller, D.K., Christ, A.N., Bruxner, T.J.C., Quinn, M.C., et al.; Australian
Pancreatic Cancer Genome Initiative (2016). Genomic analyses identify molec-
ular subtypes of pancreatic cancer. Nature 531, 47–52.
Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim,
S.Y., Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009). SOX2 is an amplified
lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
Nature Genetics 41, 1238.
Basturk, O., Khanani, F., Sarkar, F., Levi, E., Cheng, J.D., and Adsay, N.V.
(2005). DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod.
Pathol. 18, 1193–1198.
Boj, S.F., Hwang, C.-I., Baker, L.A., Chio, I.I.C., Engle, D.D., Corbo, V., Jager,
M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. (2015). Organoid models
of human and mouse ductal pancreatic cancer. Cell 160, 324–338.
Bulk, E., Sargin, B., Krug, U., Hascher, A., Jun, Y., Knop, M., Kerkhoff, C.,
Gerke, V., Liersch, R., Mesters, R.M., et al. (2009). S100A2 induces metastasis
in non-small cell lung cancer. Clin. Cancer Res. 15, 22–29.
Burtis, W.J., Wu, T., Bunch, C., Wysolmerski, J.J., Insogna, K.L., Weir, E.C.,
Broadus, A.E., and Stewart, A.F. (1987). Identification of a novel 17,000-dalton
parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor
associated with humoral hypercalcemia of malignancy. J. Biol. Chem. 262,
7151–7156.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Ja-
cobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer
genomics portal: an open platform for exploring multidimensional cancer
genomics data. Cancer Discov. 2, 401–404.
Chatterjee, A., Upadhyay, S., Chang, X., Nagpal, J.K., Trink, B., and Sidransky,
D. (2008). U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin medi-
ated degradation of DeltaNp63alpha. Cell Cycle 7, 1231–1237.
David, C.J., Huang, Y.H., Chen, M., Su, J., Zou, Y., Bardeesy, N., Iacobuzio-
Donahue, C.A., and Massague´, J. (2016). TGF-b tumor suppressor through a
lethal EMT. Cell 164, 1015–1030.
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single
transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000.
Desmet, C.J., Gallenne, T., Prieur, A., Reyal, F., Visser, N.L., Wittner, B.S.,
Smit, M.A., Geiger, T.R., Laoukili, J., Iskit, S., et al. (2013). Identification of a
pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer
metastasis. Proc. Natl. Acad. Sci. USA 110, 5139–5144.
Diaferia, G.R., Balestrieri, C., Prosperini, E., Nicoli, P., Spaggiari, P., Zerbi, A.,
and Natoli, G. (2016). Dissection of transcriptional and cis-regulatory control of
differentiation in human pancreatic cancer. EMBO J. 35, 595–617.
Ezponda, T., Dupe´re´-Richer, D., Will, C.M., Small, E.C., Varghese, N., Patel, T.,
Nabet, B., Popovic, R., Oyer, J., Bulic, M., et al. (2017). UTX/KDM6A Loss
Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells
to EZH2 inhibition. Cell Rep. 21, 628–640.
Fellmann, C., Hoffmann, T., Sridhar, V., Hopfgartner, B., Muhar, M., Roth, M.,
Lai, D.Y., Barbosa, I.A., Kwon, J.S., Guan, Y., et al. (2013). An optimizedmicro-
RNA backbone for effective single-copy RNAi. Cell Rep. 5, 1704–1713.
Feng, J., Liu, T., Qin, B., Zhang, Y., and Liu, X.S. (2012). Identifying ChIP-seq
enrichment using MACS. Nat. Protoc. 7, 1728–1740.
Ferreira, R.M.M., Sancho, R., Messal, H.A., Nye, E., Spencer-Dene, B., Stone,
R.K., Stamp, G., Rosewell, I., Quaglia, A., and Behrens, A. (2017). Duct- and
Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor
Progression and Marker Expression. Cell Rep. 21, 966–978.
Genovese, G., Carugo, A., Tepper, J., Robinson, F.S., Li, L., Svelto, M., Nezi,
L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017). Synthetic vulnerabilities of
mesenchymal subpopulations in pancreatic cancer. Nature 542, 362–366.
Grabocka, E., Pylayeva-Gupta, Y., Jones, M.J., Lubkov, V., Yemanaberhan,
E., Taylor, L., Jeng, H.H., and Bar-Sagi, D. (2014). Wild-type H- andN-Ras pro-
mote mutant K-Ras-driven tumorigenesis by modulating the DNA damage
response. Cancer Cell 25, 243–256.
GTEx Consortium (2015). Human genomics. The Genotype-Tissue Expression
(GTEx) pilot analysis: multitissue gene regulation in humans. Science 348,
648–660.
Guerra, C., Schuhmacher, A.J., Can˜amero, M., Grippo, P.J., Verdaguer, L.,
Pe´rez-Gallego, L., Dubus, P., Sandgren, E.P., and Barbacid, M. (2007).
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarci-
noma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291–302.
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X.,
Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for
macrophage and B cell identities. Mol. Cell 38, 576–589.
Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz,
M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A., et al. (2003). Preinva-
sive and invasive ductal pancreatic cancer and its early detection in themouse.
Cancer Cell 4, 437–450.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban,
R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and
KrasG12D cooperate to promote chromosomal instability and widely metasta-
tic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483.
Hodge, D.R., Hurt, E.M., and Farrar, W.L. (2005). The role of IL-6 and STAT3 in
inflammation and cancer. Eur. J. Cancer 41, 2502–2512.
Iguchi, H., Tanaka, S., Ozawa, Y., Kashiwakuma, T., Kimura, T., Hiraga, T.,
Ozawa, H., and Kono, A. (1996). An experimental model of bone metastasis
by human lung cancer cells: the role of parathyroid hormone-related protein
in bone metastasis. Cancer Res. 56, 4040–4043.
Itano, N., Atsumi, F., Sawai, T., Yamada, Y., Miyaishi, O., Senga, T., Hamagu-
chi, M., and Kimata, K. (2002). Abnormal accumulation of hyaluronanmatrix di-
minishes contact inhibition of cell growth and promotes cell migration. Proc.
Natl. Acad. Sci. USA 99, 3609–3614.
Jan, Y.H., Tsai, H.Y., Yang, C.J., Huang, M.S., Yang, Y.F., Lai, T.C., Lee, C.H.,
Jeng, Y.M., Huang, C.Y., Su, J.L., et al. (2012). Adenylate kinase-4 is a marker
of poor clinical outcomes that promotes metastasis of lung cancer by down-
regulating the transcription factor ATF3. Cancer Res. 72, 5119–5129.
Kaufmann, O., Fietze, E., Mengs, J., and Dietel, M. (2001). Value of p63 and
cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis
of poorly differentiated and undifferentiated carcinomas. Am. J. Clin. Pathol.
116, 823–830.
Kaulfuß, S., von Hardenberg, S., Schweyer, S., Herr, A.M., Laccone, F., Wolf,
S., and Burfeind, P. (2009). Leupaxin acts as a mediator in prostate carcinoma
progression through deregulation of p120catenin expression. Oncogene 28,
3971.
Keyes, W.M., Pecoraro, M., Aranda, V., Vernersson-Lindahl, E., Li, W., Vogel,
H., Guo, X., Garcia, E.L., Michurina, T.V., Enikolopov, G., et al. (2011). DNp63a
is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell
proliferation and tumorigenesis. Cell Stem Cell 8, 164–176.
Kim, D., Langmead, B., and Salzberg, S.L. (2015). HISAT: a fast spliced aligner
with low memory requirements. Nat. Methods 12, 357–360.
Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., and Spie-
gelman, B.M. (2014). Tumour-derived PTH-related protein triggers adipose
tissue browning and cancer cachexia. Nature 513, 100–104.
Kitazawa, S., Fukase, M., Kitazawa, R., Takenaka, A., Gotoh, A., Fujita, T., and
Maeda, S. (1991). Immunohistologic evaluation of parathyroid hormone-
related protein in human lung cancer and normal tissue with newly developed
monoclonal antibody. Cancer 67, 984–989.
Krebs, A.M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M.,
Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al.
(2017). The EMT-activator Zeb1 is a key factor for cell plasticity and promotes
metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518–529.
Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with
Bowtie 2. Nat. Methods 9, 357–359.
Li, C.C., Chiang, T.C., Wu, T.S., Pacheco-Rodriguez, G., Moss, J., Lee, F.J.S.,
and Barr, F. (2007). ARL4D recruits cytohesin-2/ARNO to modulate actin re-
modeling. Mol. Biol. Cell 18, 4420–4437.
Li, N., Singh, S., Cherukuri, P., Li, H., Yuan, Z., Ellisen, L.W., Wang, B.,
Robbins, D., and DiRenzo, J. (2008). Reciprocal intraepithelial interac-
tions between TP63 and hedgehog signaling regulate quiescence and
activation of progenitor elaboration by mammary stem cells. Stem Cells
26, 1253–1264.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Sub-
group (2009). The Sequence Alignment/Map format and SAMtools. Bioinfor-
matics 25, 2078–2079.Cell Reports 25, 1741–1755, November 13, 2018 1753
Lin, C.Y., Erkek, S., Tong, Y., Yin, L., Federation, A.J., Zapatka, M., Hal-
dipur, P., Kawauchi, D., Risch, T., Warnatz, H.-J., et al. (2016). Active
medulloblastoma enhancers reveal subgroup-specific cellular origins.
Nature 530, 57–62.
Liu, N., Gao, F., Han, Z., Xu, X., Underhill, C.B., and Zhang, L. (2001). Hyalur-
onan synthase 3 overexpression promotes the growth of TSU prostate cancer
cells. Cancer Res. 61, 5207–5214.
McDonald, O.G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S.J.,
Warmoes, M.O., Word, A.E., Carrer, A., Salz, T.H., Natsume, S., et al.
(2017). Epigenomic reprogramming during pancreatic cancer progression
links anabolic glucose metabolism to distant metastasis. Nat. Genet. 49,
367–376.
McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T., Lowe, C.B.,
Wenger, A.M., and Bejerano, G. (2010). GREAT improves functional interpre-
tation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501.
Memmi, E.M., Sanarico, A.G., Giacobbe, A., Peschiaroli, A., Frezza, V.,
Cicalese, A., Pisati, F., Tosoni, D., Zhou, H., Tonon, G., et al. (2015).
p63 Sustains self-renewal of mammary cancer stem cells through regu-
lation of Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. USA 112,
3499–3504.
Mills, A.A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D.R., and Bradley, A.
(1999). p63 is a p53 homologue required for limb and epidermal morphogen-
esis. Nature 398, 708–713.
Moffitt, R.A., Marayati, R., Flate, E.L., Volmar, K.E., Loeza, S.G.H., Hoadley,
K.A., Rashid, N.U.,Williams, L.A., Eaton, S.C., Chung, A.H., et al. (2015). Virtual
microdissection identifies distinct tumor- and stroma-specific subtypes of
pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168–1178.
Morohoshi, T., Held, G., and Klo¨ppel, G. (1983). Exocrine pancreatic tumours
and their histological classification. A study based on 167 autopsy and 97 sur-
gical cases. Histopathology 7, 645–661.
Pen˜a, C., Ce´spedes, M.V., Lindh, M.B., Kiflemariam, S., Mezheyeuski, A.,
Edqvist, P.H., Ha¨gglo¨f, C., Birgisson, H., Bojmar, L., Jirstro¨m, K., et al.
(2013). STC1 expression by cancer-associated fibroblasts drives metastasis
of colorectal cancer. Cancer Res 73, 1287–1297.
Peterson, E.A., Jenkins, E.C., Lofgren, K.A., Chandiramani, N., Liu, H., Aranda,
E., Barnett, M., and Kenny, P.A. (2015). Amphiregulin is a critical downstream
effector of estrogen signaling in ERa-positive breast cancer. Cancer Res. 75,
4830–4838.
Petitjean, A., Ruptier, C., Tribollet, V., Hautefeuille, A., Chardon, F., Cavard, C.,
Puisieux, A., Hainaut, P., and Caron de Fromentel, C. (2008). Properties of the
six isoforms of p63: p53-like regulation in response to genotoxic stress and
cross talk with DeltaNp73. Carcinogenesis 29, 273–281.
Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for
comparing genomic features. Bioinformatics 26, 841–842.
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S.A., Flynn, R.A., and
Wysocka, J. (2011). A unique chromatin signature uncovers early develop-
mental enhancers in humans. Nature 470, 279–283.
Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F.,
Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al. (2012).
EMT and dissemination precede pancreatic tumor formation. Cell 148,
349–361.
Rocco, J.W., Leong, C.-O., Kuperwasser, N., DeYoung,M.P., and Ellisen, L.W.
(2006). p63 mediates survival in squamous cell carcinoma by suppression of
p73-dependent apoptosis. Cancer Cell 9, 45–56.
Roe, J.S., Hwang, C.I., Somerville, T.D.D., Milazzo, J.P., Lee, E.J., Da Silva, B.,
Maiorino, L., Tiriac, H., Young, C.M., Miyabayashi, K., et al. (2017). Enhancer
Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170, 875–
888.e20.
Saldanha, A.J. (2004). Java Treeview–extensible visualization of microarray
data. Bioinformatics 20, 3246–3248.
Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z.,
Thomas, R.K., Greulich, H., Schinzel, A., et al. (2010). An activated ErbB3/1754 Cell Reports 25, 1741–1755, November 13, 2018NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
Cancer Cell 17, 298–310.
Shi, J., Wang, E., Milazzo, J.P., Wang, Z., Kinney, J.B., and Vakoc, C.R. (2015).
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein do-
mains. Nat. Biotechnol. 33, 661–667.
Shrestha, P., Muramatsu, Y., Kudeken, W., Mori, M., Takai, Y., Ilg, E.C.,
Schafer, B.W., and Heizmann, C.W. (1998). Localization of Ca(2+)-bind-
ing S100 proteins in epithelial tumours of the skin. Virchows Arch. 432,
53–59.
Siegel, R.L., Miller, K.D., and Jemal, A. (2018). Cancer statistics, 2018. CA
Cancer J. Clin. 68, 7–30.
Soares, E., and Zhou, H. (2018). Master regulatory role of p63 in epidermal
development and disease. Cell. Mol. Life Sci. 75, 1179–1190.
Su, X., Chakravarti, D., Cho, M.S., Liu, L., Gi, Y.J., Lin, Y.-L., Leung, M.L., El-
Naggar, A., Creighton, C.J., Suraokar, M.B., et al. (2010). TAp63 suppresses
metastasis through coordinate regulation of Dicer and miRNAs. Nature 467,
986–990.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.
Tadeu, A.M.B., and Horsley, V. (2013). Notch signaling represses p63 expres-
sion in the developing surface ectoderm. Development 140, 3777–3786.
Tarumoto, Y., Lu, B., Somerville, T.D.D., Huang, Y.-H., Milazzo, J.P., Wu, X.S.,
Klingbeil, O., El Demerdash, O., Shi, J., and Vakoc, C.R. (2018). LKB1, Salt-
Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid
Leukemia. Mol. Cell 69, 1017–1027.e6.
The Cancer Genome Atlas Research Network (2017). Integrated genomic
characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–
203.e13.
Thomas-Chollier, M., Hufton, A., Heinig, M., O’Keeffe, S., Masri, N.E., Roider,
H.G., Manke, T., and Vingron, M. (2011). Transcription factor binding predic-
tions using TRAP for the analysis of ChIP-seq data and regulatory SNPs.
Nat. Protoc. 6, 1860–1869.
Tiriac, H., Belleau, P., Engle, D.D., Plenker, D., Desche^nes, A., Somerville,
T.D.D., Froeling, F.E.M., Burkhart, R.A., Denroche, R.E., Jang, G.-H., et al.
(2018). Organoid profiling identifies common responders to chemotherapy in
pancreatic cancer. Cancer Discov. 8, 1112–1129.
Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van
Baren, M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript
assembly and quantification by RNA-seq reveals unannotated transcripts
and isoform switching during cell differentiation. Nat. Biotechnol. 28,
511–515.
Urosevic, J., Garcia-Albe´niz, X., Planet, E., Real, S., Ce´spedes, M.V., Guiu, M.,
Fernandez, E., Bellmunt, A., Gawrzak, S., Pavlovic, M., et al. (2014). Colon can-
cer cells colonize the lung from established liver metastases through p38
MAPK signalling and PTHLH. Nat. Cell Biol. 16, 685–694.
Waugh, D.J.J., and Wilson, C. (2008). The interleukin-8 pathway in cancer.
Clin. Cancer Res. 14, 6735–6741.
Witkiewicz, A.K., McMillan, E.A., Balaji, U., Baek, G., Lin, W.C., Mansour, J.,
Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015). Whole-exome
sequencing of pancreatic cancer defines genetic diversity and therapeutic
targets. Nat. Commun. 6, 6744.
Xi, Y., Kim, T., Brumwell, A.N., Driver, I.H., Wei, Y., Tan, V., Jackson, J.R., Xu,
J., Lee, D.K., Gotts, J.E., et al. (2017). Local lung hypoxia determines epithelial
fate decisions during alveolar regeneration. Nat. Cell Biol. 19, 904–914.
Xu, Y., Milazzo, J.P., Somerville, T.D.D., Tarumoto, Y., Huang, Y.-H.,
Ostrander, E.L., Wilkinson, J.E., Challen, G.A., and Vakoc, C.R. (2018). A
TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid
Leukemia. Cancer Cell 33, 13–28.e8.
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M.D., Do¨tsch, V.,
Andrews, N.C., Caput, D., and McKeon, F. (1998). p63, a p53 homolog at
3q27-29, encodes multiple products with transactivating, death-inducing, and
dominant-negative activities. Mol. Cell 2, 305–316.
Ye, L.Y., Chen,W., Bai, X.L., Xu, X.Y., Zhang, Q., Xia, X.F., Sun, X., Li, G.G., Hu,
Q.D., Fu, Q.H., and Liang, T.B. (2016). Hypoxia-Induced Epithelial-to-
Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immuno-
suppressive Tumor Microenvironment to Promote Metastasis. Cancer Res.
76, 818–830.Young, A., Lou, D., and McCormick, F. (2013). Oncogenic and wild-type Ras
play divergent roles in the regulation of mitogen-activated protein kinase
signaling. Cancer Discov. 3, 112–123.
Zhang, J., Ji, J.Y., Yu, M., Overholtzer, M., Smolen, G.A., Wang, R., Brugge,
J.S., Dyson, N.J., and Haber, D.A. (2009). YAP-dependent induction of
amphiregulin identifies a non-cell-autonomous component of the Hippo
pathway. Nature Cell Biology 11, 1444.Cell Reports 25, 1741–1755, November 13, 2018 1755
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-TP63 (for WB, IHC and ChIP) Cell Signaling Cat# 39692; RRID: N/A
Rabbit polyclonal anti-KRT5/6 (for WB) Millipore Cat# MAB1620; RRID: AB_94292
Rabbit polyclonal anti-S100A2 (for WB and HIC) Abcam Cat# ab109494; RRID: AB_10859000
ImmPRESS Horse-Anti-Rabbit Ig Reagent
antibody (IHC)
Vector Cat# MP-7401; RRID: AB_2336529
ImmPRESS Horse-Anti-Mouse Ig Reagent
antibody (IHC)
Vector Cat# MP-7402; RRID: AB_2336528
Mouse monoclonal anti-HSC70 (for WB) Santa Cruz Biotechnology Cat# sc-7298; RRID: AB_627761
Rabbit polyclonal anti-H3K27ac (for ChIP) Abcam Cat# ab4729; RRID: AB_2118291
Rabbit polyclonal anti-MYC (for ChIP) Abcam Cat# ab32072; RRID: AB_731658
Mouse monoclonal anti-FLAG (for ChIP) Sigma-Aldrich Cat# F1804; RRID: AB_262044
Chemicals, Peptides, and Recombinant Proteins
10% Neutral Buffered Formalin Thermal Fisher Scientific Cat# 22-110-869
2-Mercaptoethanol Sigma-Aldrich Cat# M6250
Isopropanol Sigma-Aldrich Cat# 190674
2x Laemmli Sample Buffer BIO-RAD Cat# 1610737
Chloroform Sigma-Aldrich Cat# 288306
DNase I (RNase-free) New England Biolabs Cat# M0303S
Formaldehyde, 37% solution Avantor Cat# 2106-01
Glycine Thermal Fisher Scientific Cat# BP381-1
Penicillin/Streptomycin Thermal Fisher Scientific Cat# 15140122
Polybrene EMD Millipore Cat# TR-1003-G
Polyethylenimine, Linear, MW 25,000 (PEI 25000) Polysciences Cat# 23966-1
TRIzol Reagent Thermo Fisher Cat# 15596018
D-Luciferin Goldbio Cat# 115144-35-9
Geneticin Selective Antibiotic (G-418 Sulfate) Thermal Fisher Scientific Cat# 10131035
Puromycin dihydrochloride Sigma-Aldrich Cat# P8833
Blasticidin S HCl Thermal Fisher Scientific Cat# A1113903
DMEM with 4.5 g/L glucose, L-glutamine &
sodium pyruvate
Cellgro Cat# 10-013-CV
Advanced DMEM/F12 Life Technologies Cat# 12634-028
RPMI 1640 w/ L-glutamine Fisher Scientific Cat# MT10040CV
HEPES Life Technologies Cat# 15630-130
Glutamax Life Technologies Cat# 35050-079
AB3-01 Tocris Bioscience Cat# 2939
hEGF PeproTech Cat# AF-100-15
mNoggin PeproTech Cat# 250-38
hFGF10 PeproTech Cat# 100-26
hGastrin Tocris Bioscience Cat# 3006
N-acetylcysteine Sigma-Aldrich Cat# A9165-5G
Nicotinamide Sigma-Aldrich Cat# N0636-100G
PGE2 Tocris Bioscience Cat# 2296
B27 supplement Life Technologies Cat# 17504044
R-Spondin 1 Cells Trevigen Cat# 3710-001-K
(Continued on next page)
e1 Cell Reports 25, 1741–1755.e1–e7, November 13, 2018
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Afamin/Wnt3A conditioned media Osaka University N/A
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Human PDA cell line PATU8988S DSMZ Cat# ACC 204
Human PDA cell line HPAFII ATCC Cat# CRL-1997
Human PDA cell line AsPC1 ATCC Cat# CRL-1682
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Human PDA cell line PANC1 ATCC Cat# CRL-1469
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Murine PDA cell line FC1245 David Tuveson N/A
Experimental Models: Organisms/Strains
Mouse: NSG The Jackson Laboratory Stock # 005557
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Oligonucleotides
sgRNA/shRNA/RT-PCR sequences see Table S7 This paper N/A
Recombinant DNA
deltaNp63alpha-FLAG (Chatterjee et al., 2008) Addgene plasmid #26979
LentiV-DNp63-FLAG-neo This paper N/A
Lenti-luciferase-blast This paper N/A
LentiV-Cas9-puro (Tarumoto et al., 2018) Addgene plasmid #108100
LRNG (Lenti_sgRNA_EFS_Neo-IRES-GFP) (Roe et al., 2017) N/A
LRG2.1 (Tarumoto et al., 2018) Addgene plasmid #108098
LEPG (LTR-miRE-shRNA-PGK-puro-IRES-GFP) (Fellmann et al., 2013) Addgene plasmid #111160
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LivingImage
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Chris-
topher Vakoc (vakoc@cshl.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animal procedures and studies were approved by the Cold Spring Harbor Laboratory Animal Care and Use Committee in accor-
dance to IACUC. Six- to ten-week old female NSG mice used for transplant studies were purchased from the Jackson Laboratory.
Cell Lines
PATU8988S, HPAFII, AsPC1, SUIT2, CFPAC1, PANC1, MIAPaca2 and BxPC3 cells were cultured in RPMI supplemented with 10%
FBS (R10). FC1199, FC1242 and FC245were derived from KPC (Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx1-Cre) mice and cultured
in DMEM with 10% FBS. hN30, N34, hN35, hT85, hF2 and hF3 (human organoid samples) were established and cultured ase3 Cell Reports 25, 1741–1755.e1–e7, November 13, 2018
described in detail elsewhere (Tiriac et al., 2018). Briefly, cells were plated with Matrigel and grown in Human complete Feeding
Medium (hCPLT): advanced DMEM/F12, HEPES 10mM, Glutamax 1X, A83-01 500nM, hEGF 50ng/mL, mNoggin 100ng/mL,
hFGF10 100ng/mL, hGastrin I 0.01 mM, N-acetylcysteine 1.25mM, Nicotinamide 10mM, PGE2 1 mM, B27 supplement 1X final,
R-spondin1 conditioned media 10% final, Afamin/Wnt3A conditioned media 50% final. HEK293T cells were cultured in DMEM
with 10% FBS. Penicillin/streptomycin were added to all cell culture. HEK293T cells were used for packaging lentivirus using poly-
ethylenimine (PEI)-mediated transfection.
METHOD DETAILS
Plasmid Construction
For generation of the LentiV-DNp63-neo vector, DNp63 cDNA from the detlaNp63-FLAG vector (addgene #26979) (Chatterjee et al.,
2008) was subcloned to LentiV-Cas9-puro vector (addgene #108100) (Tarumoto et al., 2018) in place of Cas9 and the puromycin
resistance cassette was replaced with a neomycin resistance cassette. For the LentiV-neo empty vector, Cas9 was replaced with
a 3*FLAG sequence (Xu et al., 2018). For generation of the LentiV-DNp63-FLAG-neo vector, a 3*FLAG sequence was added to
the C terminus of DNp63 cDNA in the LentiV-DNp63-neo vector. To generate Lenti-luciferase-blast vector the luciferase transgene
from Lenti-luciferase-P2A-Neo vector (addgene #105621) to a vector with blasticidin resistance. For experiments involving dox-
regulated expression, cells were infected with DNp63 or GFP cDNA in the dox-regulated vector YXP (TREtight-cDNA-EFS-rtTA-
P2A-Puro) and selected with puromycin (3 mg/ml).
Lentiviral Production and Infection
Lentivirus was produced in HEK293T cells by transfecting plasmids and packaging plasmids (VSVG and psPAX2) using PEI. Media
was replaced with R10 media 6-8 hours following transfection and lentivirus-containing supernatant was subsequently collected
every 12 hours for 48 hours prior to filtration through a 0.45 mm filter. For infection of cells, cell suspensions were mixed with
lentiviral-containing supernatant supplemented with polybreane to a final concentration of 4 mg/ml. Cells were plated in tissue culture
plates of the appropriate size and lentiviral-containing supernatant was replaced with fresh media after an incubation period of
6-8 hours.
In Vitro Phenotypic Assays
SUIT2 cells were first infected with DNp63 cDNA in LentiV-DNp63-neo vector or the empty vector as a control. Two days post infec-
tion, transduced cells were selected with 1 mg/ml of G418 and on day seven post infection, cells were counted by trypan blue exclu-
sion and used for the assays described below.
For cell growth assays, 200 cells were plated in quadruplicate in 20 mL of media in each well of a 384-well plate. Quantification of
viable cells was determined every 24 hours post seeding for a total of six days using CellTiterGlo Luminescent Cell Viability Assay kit
(Promega) and a SpectraMax plate reader (Molecular Devices) following the manufacture’s protocol.
For 3DMatrigel colony formation assays, 5,000 cells were resuspended in 1ml RPMI supplemented with 5%Matrigel and 2% FBS
and plated in triplicate in eachwell of an ultra-low attachment 24-well plate (Corning). Bright field images were captured on day seven
post plating and colony size and number were quantified from four 4x images per well using ImageJ software (NIH).
For scratch assays, cells were first plated to confluency in triplicate in wells of a standard 24-well plate. At day 0 of the assay, a
wound was applied down the center of the well using a pipette tip. Media was subsequently removed and cells washed with PBS
before addition of 1ml serum-free RPMI. Bright field images were captured using a 4x objective immediately (0 hours) and then at
6 hours and 24 hours post plating. Area of the wound was quantified using ImageJ software (NIH).
CRISPR-Based Targeting
For GFP-depletion assays, cells stably expressing Cas9 in LentiV-Cas9-puro vector were infected with sgRNAs in LRG2.1 vector
(addgene #108098). GFP% was measured on day three (P0) and then every three days post viral transduction until the end of the
experiment.
For RNA-seq experiments of CRISPR based targeting of TP63 in BxPC3 cells, BxPC3 cells stably expressing Cas9 were infected
with control or TP63 sgRNAs in LRNG vector. Two days post infection with sgRNAs, transduced cells were selected with 1mg/ml of
G418 and on day five post infection cells were used for RNA-seq analysis.
For CRISPR based targeting of TP63 in BxPC3 cells in vivo, please refer to the in vivo transplantation experiments section. sgRNA
sequences can be found in Table S7.
shRNA targeting in BxPC3 cells and hF3 organoids
shRNAs targeting TP63 or control were cloned into the miR-E-based retroviral shRNA expression vector LEPG (LTR-miRE-shRNA-
PGK-puro-IRES-GFP) (addgene #111160) (Fellmann et al., 2013). For GFP depletion assays in BxPC3 cells, GFP%wasmeasured on
day three (P0) and then every three days post viral transduction until the end of the experiment. For cell growth assays in hF3 organo-
ids, cells were first infected with the appropriate lentiviral supernatant and at three days post infection, transduced cells were
selected with 2 mg/ml of puromycin for five days. On day eight post infection, cells were counted by trypan blue exclusion andCell Reports 25, 1741–1755.e1–e7, November 13, 2018 e4
500 cells were plated in triplicate in 30 mL of hCPLT media supplemented with 10% Matrigel in each well of a 384-well plate.
Quantification of viable cells was determined every 24 hours post seeding for a total of seven days using CellTiterGlo Luminescent
Cell Viability Assay kit (Promega) and a SpectraMax plate reader (Molecular Devices) following the manufacture’s protocol.
For RNA-seq experiments of shRNA-mediated targeting of TP63 in BxPC3 cells and hF3 organoids, cells were infectedwith control
or TP63 shRNAs in MLS-E vector and at two days (for BxPC3 cells) or three days (for hF3 organoids) post infection with shRNAs,
transduced cells were selected with 2 mg/ml of puromycin and on day five (for BxPC3 cells) or day eight (for hF3 organoids) post infec-
tion cells were used for RNA-seq analysis. shRNA sequences can be found in Table S7.
In Vivo Transplantation Experiments
All animal procedures and studies were approved by the Cold Spring Harbor Laboratory Animal Care and Use Committee in accor-
dance to IACUC.
For CRISPR-mediated targeting of TP63 in BxPC3 cells in vivo, BxPC3 cells stably expressing Cas9 were first infected with a lucif-
erase transgene in Lenti-luciferase-blast vector and a stable cell line was generated by selection with 10 mg/ml blasticidin. These cells
were subsequently infected with control or TP63 sgRNA in LRNG vectors. Two days post infection with sgRNAs, transduced cells
were selected with 1mg/ml of G418 for three days and on day five post infection, cells were counted by trypan blue exclusion,
resuspended in PBS and kept on ice prior to transplantation.
For in vivo experiments using reprogrammed SUIT2 cells, parental SUIT2 cells were first infected with a luciferase transgene in
Lenti-luciferase-blast vector and a stable cell line was generated by selection with 10 mg/ml blasticidin. These cells were subse-
quently infected DNp63 cDNA in LentiV-DNp63-neo vector or the empty vector as a control. Two days post infection, transduced
cells were selected 1 mg/ml of puromycin for three days and on day five post infection, cells were counted by trypan blue exclusion,
resuspended in PBS and kept on ice prior to transplantation.
For lung colonization assays, 100,000 viable SUIT2 cells or 250,000 viable BxPC3 cells in 200 mL PBSwere injected into the tail vein
of NSG mice and bioluminescence imaging was initiated on day seven post transplantation.
Orthotopic transplants of cells into the pancreas ofmicewere performed as previously described (Aiello et al., 2016). Briefly, 50,000
viable SUIT2 cells or 100,000 viable BxPC3 cells in 50 mL of PBS were slowly injected into the body of the pancreas. Following bleb
formation, the pancreaswas carefully put back in place before suturing the peritoneal cavity and closing the skin incision usingwound
clips. Wound clips were removed on day seven post transplantation prior to bioluminescence imaging.
For bioluminescence imaging, mice were intraperitoneally (IP) injected with D-Luciferin (50mg/kg) and analyzed using an IVIS
Spectrum system (Caliper Life Sciences) ten minutes post IP injection.
Histology and Immunohistochemistry
For histological and immunohistochemical analysis of mouse tissues, tissues were fixed in 10% neutral buffered formalin at room
temperature for 24 hours andwashedwith 70%ethanol. Sampleswere then processed and subjected toH&E staining following stan-
dard protocol at the CSHL histology core facility. For immunohistochemical analysis, 6 mmFFPE tissues sectionswere deparaffinized
and rehydrated prior to steam based antigen retrieval in citrate buffer (pH 6.0). Sections were washed with dH2O prior to 10 minute
incubation with 3% H2O2 to block endogenous peroxidase activity. Following 5 minutes rinse with dH2O, sections were incubated
with 2.5%normal horse serum (Vector) for 1 hour at room temperature. Sections were subsequently incubated with 100 mL of primary
antibody at the following dilutions in TBST: anti-TP63 (1:500), anti-KRT5/6 (1:200) or anti-S100A2 (1:250). Following washes, sections
were then incubated for 1 hour at room temperature with HRP-linked horse-anti-mouse (for anti-KRT5/6) or horse-anti-rabbit (for anti-
TP63 and anti-S100A2) secondary antibodies. Following further wash steps antigen labeling was performed using ImmPACT DAB
(3,3-diamionbenzidine) peroxidase substrate kit (Vector) with 1-2 minute incubation. Sections were washed thoroughly, hematoxylin
counterstained, dehydrated and coverslipped. Images were taken on an Axio Imager.A2 (ZEISS) microscope with a 20x objective.
Cell Lysate Preparation for Western Blot Analysis
Cell cultures were collected and 1million cells were counted by trypan blue exclusion and washed with ice cold PBS. Cells were then
resuspended in 100 mL PBS and lysed with 100 mL of 2x Laemmli Sample Buffer supplemented with b-mercaptoethanol by boiling for
30 minutes.
RNA Extraction and RT-PCR
Total RNA was extracted using TRIzol reagent following the manufacturer’s instructions. For RNA extraction from organoid samples,
organoids were lysed by adding TRIzol reagent directly to the Matrigel dome. 1-2 mg of total RNA was treated with DNaseI and
reverse transcribed to cDNA using qScript cDNA SuperMix, followed by RT-qPCR analysis with SYBR green PCR master mix on
an ABI 7900HT fast real-time PCR system.
RNA-seq Library Construction
RNA-seq libraries were constructed using the TruSeq sample Prep Kit V2 (Illumina) according to the manufacturer’s instructions.
Briefly, 2 mg of purified RNA was poly-A selected and fragmented with fragmentation enzyme. cDNA was synthesized with Supere5 Cell Reports 25, 1741–1755.e1–e7, November 13, 2018
Script II master mix, followed by end repair, A-tailing and PCR amplification. RNA-seq libraries were single-end sequenced for 50bp
using an Illumina HighSeq2500 or NextSeq platform (Cold Spring Harbor Genome Center, Woodbury).
ChIP and ChIP-Seq Library Construction
Cell cultures and organoid cultures were collected as single cell suspensions andwere crosslinked in 1% formaldehyde at room tem-
perature for 20 min and the reaction was then quenched using 0.125M glycine. 5-10 million cells were incubated with cell lysis buffer
(10mMTris pH8.0, 10mMNaCl, 0.2%NP-40) and then resuspended and sonicated in 500 mL of nuclei lysis buffer (50mMTris pH8.0,
10mMEDTA, 1%SDS) for 15min using a BioRuptor water bath sonicator (medium setting, 30 s ON/OFF cycles). 500 mL of sonicated
chromatin from 5-10million cells was dilutedwith 7.5ml of IP-Dilution buffer (20mMTris pH 8.0, 2mMEDTA, 150mMNaCl, 1%Triton
X-100, 0.01% SDS) and incubated with 2 mg of the appropriate antibody and 25 mL of magnetic beads (protein A beads for rabbit
antibody, protein G beads for mouse antibody) at 4C overnight. After washing once with 1ml IP-wash 1 buffer (20 mM Tris
pH8.0, 2 mM EDTA, 50 mM NaCl, 1% Triton X-100, 0.1% SDS), twice with 1ml High-salt buffer (20 mM Tris pH 8.0, 2 mM EDTA,
500 mM NaCl, 1% Triton X-100, 0.01% SDS), once with 1ml IP-wash 2 buffer (10 mM Tris pH 8.0, 1 mM EDTA 0.25 M LiCl, 1%
NP-40, 1% sodium deoxycholate), twice with 1ml TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH 8.0), beads bound to chromatin
were eluted in 200 mL nuclei lysis buffer by heating at 65C for 15 min at 1000rpm. 12 mL of 5M NaCl and 2 mL RNaseA (stock at
1mg/ml) was then added to the 200 mL eluted chromatin, followed by incubation at 65C overnight for reverse cross-linking. DNA
was subsequently treated with proteinase K for 2 hours at 42C and then purified using a QIAGEN PCR purification kit.
ChIP-seq library was constructed using Illumina TruSeq ChIP Sample Prep kit following manufacture’s protocol. Briefly, ChIP DNA
was end repaired, followed by A-tailing and size selection (300-500bp) by gel electrophoresis using a 2% gel. 15 PCR cycles were
used for final library amplification which was analyzed on a Bioanalyzer using a high sensitivity DNA chip (Agilent). ChIP-seq libraries
were single-end sequenced for 50bp using an Illumina NextSeq platform (Cold Spring Harbor Genome Center, Woodbury).
RNA-Seq Data Analysis
Single end 50bp sequencing reads were mapped to the hg19 genome using HISAT2 (Kim et al., 2015). Structural RNA was masked
and differentially expressed genes were identified using Cuffdiff (Trapnell et al., 2010). All the following analysis was performed on
genes with an RPKM value no less than 2 in either control or experimental samples. For RNA-seq following CRISPR based targeting
of TP63 in BxPC3 cells, fold-change in RPKMwas calculated as the ratio of the mean RPKM value of two independent TP63 sgRNAs
to the RPKM value of the control sgRNA. For RNA-seq following ectopic expression of DNp63 in PATU8988S or SUIT2 cells, fold-
change in RPKM was calculated as ratio of mean RPKM value of samples expressing DNp63 from two biological repeats to the
mean RPKM value of control samples infected with an empty vector.
RNA-seq analysis of patient samples was performed using data extracted from Bailey et al. (2016). Only protein coding genes with
a cpm value greater than 4 in at least 10% of the 96 patient samples for which RNA-seq data was available were used. The top 500
and bottom 500 genes passing this expression threshold in Squamous versus Progenitor samples, as defined by Bailey et al. (2016),
defined the Squamous-PDA and Progenitor-PDA Identity signatures, respectively. To generate a ranked gene list for Pre-ranked
gene set enrichment analysis (GSEA) (Subramanian et al., 2005), genes were ranked by their mean log2 fold change in Squamous
versus Progenitor PDA patient samples. Heatmaps of standardized expression values were generated using Morpheus from the
Broad Institute.
ChIP-Seq Analysis
Single end 50bp sequencing reads were mapped to the hg19 genome using Bowtie2 with default settings (Langmead and Salzberg,
2012). After removing duplicated mapped reads using SAM tools (Li et al., 2009), MACS 1.4.2 was used to call peaks using input
genomic DNA as control (Feng et al., 2012). Only peaks enriched greater than or equal to 10-fold over input samples were used
for subsequent analyses. Annotation of ChIP-seq peaks was performed using HOMER v4.9 with default settings (Heinz et al., 2010).
For unsupervised hierarchical clustering of the nine cell cultures representing human PDA and normal ducts, H3K27ac peaks from
all samples were combined using the mergePeaks tool from HOMER v4.9 using default settings (-d given). This yielded a union of all
H3K27ac peaks (n = 68,043). ChIP-seq tag counts were then recalculated at these intervals usingMultCovBed fromBEDTools (Quin-
lan and Hall, 2010) and were normalized to a read depth of 10 million uniquely mapped reads. Normalized H3K27ac tag counts were
then used to generate a heatmap of similaritymatrix by Pearson correlation, whichwas subsequently clustered by Euclidean distance
with average linkage using Morpheus from the Broad Institute.
To define ‘Squamous Elements’, regions with greater than 1 tag per million in either hF3 or BxPC3 cells were used to calculate the
ratio of the H3K27ac tag counts in hF3 or BxPC3 cells versus the mean tag counts across the other seven cultures. Those regions
found to be greater than 5-fold increased in both hF3 andBxPC3 cells were defined as Squamous Elements (n = 1,336). A randomized
set of 1,336 regions from the union of all H3K27ac peaks across the nine cultures were used as control regions (Random elements).
Heatmap density plots were made by first generating a density matrix by mapping sequencing reads from each ChIP-seq exper-
iment to the 200 100bp bins around the center of a defined set of H3K27ac regions, i.e., Squamous elements, Random elements or All
elements, with the latter defined as all H3K27ac peaks from the parental cell line. TreeView software was used to generate the heat-
map from the density matrix and the contrast was adjusted proportionally to the total uniquely mapped reads for visual comparison
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For calculating fold-change of H3K27ac tag counts following CRISPR based targeting of TP63 in BxPC3 cells, the following anal-
ysis was performed. First, H3K27ac peaks from cells infected with control and the two independent TP63 sgRNAs were combined
using the mergePeaks tool to yield a union of all H3K27ac peaks in BxPC3 cells. ChIP-seq tag counts were then recalculated and
normalized to a read depth of 1million uniquelymapped reads. Regions with greater than or equal to 5 tags permillion in either control
or TP63 knockout samples were then used to calculate the fold-change in tags as the ratio of the mean tag count of the two inde-
pendent TP63 sgRNAs to the tag count in the control sample. Regions that decreased greater than 3-fold following TP63 knockout
were defined as repressed (n = 741) and those that increased greater than 3-fold were defined as activated (n = 330). The same pipe-
line was used for calculating fold-change of H3K27ac tag counts following ectopic DNp63 expression in SUIT2 cells compared to
those infectedwith an empty vector control. ThoseH3K27ac regions that increased greater than 3-fold inDNp63 cells versus controls
were defined as activated (n = 1,335) and those that decreased greater than 3-fold were defined as repressed (n = 79).
For GSEA analysis, the nearest expressed genes (RPKMR 2) in hF3 or BxPC3 cells to Squamous Elements were first identified
using Genomic Regions Enrichment of Annotations Tool (GREAT) (McLean et al., 2010). If the two nearest genes had an RPKM < 2 in
both hF3 and BxPC3 cells, the peak was abandoned. This yielded 668 genes that were used for GSEA using the ranked gene list
prepared from the analysis of Squamous versus Progenitor PDA patient samples.
Ontology analysis of Squamous elements and Random elements was also performed using GREAT with whole genome set as
background using the basal plus extension setting.
For TRAP analysis (Thomas-Chollier et al., 2011), DNA sequences flanking 500bp from the center of each H3K27ac peak were ex-
tracted from the hg19 genome using the UCSC table browser. These regions served as the input to find enriched JASPAR vertebrate
motifs with human promoters as the background using the Benjamini-Hochber correction. Fold enrichment was calculated as the
ratio +1 of the observed p value (-log10) at Squamous versus Random elements.
For TP63 ChIP-seq analysis in BxPC3 cells, motif discovery was performed on all peaks using MEME-ChIP from the MEME Suite
(Bailey et al., 2009). Annotation of ChIP-seq peaks was performed using HOMER v4.9 with default settings (Heinz et al., 2010).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was evaluated by p value from two-tailed Student’s t test or ANOVA using Prism software as indicated in
the figure legends. Data are presented as mean with SEM and statistical significance of p value is indicated in figure legends.
Unless otherwise stated in the figure legend, n refers to the number of biological repeats. For Kaplan-Meier survival curves, the
log rank (Mantel-Cox) test was used to estimate median overall survival and statistical significance. Survival data were obtained
from the CBioPortal (TCGA-PAAD) (Cerami et al., 2012), ICGC Data Portal (PACA-AU) (Bailey et al., 2016) or from the study by
Moffitt et al. (2015). Survival data from the CBioPortal and the ICGC Data Portal data were downloaded in January 2018. For the
TCGA-PAAD study, only the 150 confirmed PDA cases were used for the analyses in this study (The Cancer Genome Atlas
Research Network, 2017).
DATA AND SOFTWARE AVAILABILITY
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